Advertisement

Addressing the Lack of Competition in Generic Drugs to Improve Healthcare Quality and Safety

  • Karthik Sivashanker
  • John Fanikos
  • Allen Kachalia
Perspective

Abstract

A lack of access to critical drugs in the USA, either due to exorbitant prices or shortages, has become a troubling norm that threatens the quality and safety of healthcare. In 2017, there were shortages of 146 commonly used drugs including electrolytes, chemotherapy, cardiovascular, and antibiotic agents. For example, there currently exists a shortage in intravenous fluids and injectable opioids (both in chronic short supply for years) that has been respectively ascribed to disruptions in pharmaceutical manufacturing by Hurricane Maria and manufacturing delays. These explanations, however, mask a more fundamental and avoidable cause: a lack of healthy competition in the generic drug market which is likely contributing to price hikes and shortages. By understanding this underlying cause, we hope to illuminate a pathway from our current state of complacency, where drug price hikes and shortages are routine, to a future state of effective action, where patients have reliable access to vital drugs. This article outlines a roadmap to influence incentives, regulations, new drug development, and ultimately stakeholder (i.e., patients, providers, and drug makers) behavior to enhance competition, with the ultimate aim of improving the quality and safety of healthcare for our patients.

KEY WORDS

quality safety public health health economics 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors that they do not have conflict of interest.

References

  1. 1.
    Fox E. Drug Shortages Statistics. 2018. Retrieved May 29th, 2018, from https://www.ashp.org/Drug-Shortages/Shortage-Resources/Drug-Shortages-Statistics.
  2. 2.
    Pear R. Drug Company ‘Shenanigans’ to Block Generics Come Under Federal Scrutiny. 2018. Retrieved May 29th, 2018, from https://www.nytimes.com/2018/04/14/us/politics/drug-companies-generic.html.
  3. 3.
    Loftus P. States Expand Price-Fixing Accusations Against Generic Drug Companies. 2017. Retrieved May 29th, 2018, from https://www.wsj.com/articles/more-states-seek-to-sue-drug-companies-over-price-fixing-allegations-1509478848.
  4. 4.
    Vail E, Gershengorn HB, Hua M, Walkey AJ, Rubenfeld G, Wunsch H. Association Between US Norepinephrine Shortage and Mortality Among Patients With Septic Shock. JAMA 2017;317(14):1433–1442.  https://doi.org/10.1001/jama.2017.2841 CrossRefPubMedGoogle Scholar
  5. 5.
    Mazer-Amirshahi M, Fox ER. Saline Shortages — Many Causes, No Simple Solution. N Engl J Med 2018;378(16):1472–1474.  https://doi.org/10.1056/nejmp1800347 CrossRefPubMedGoogle Scholar
  6. 6.
    Frank R, Ginsburg P. Pharmaceutical industry profits and research and development. 2017. Retrieved May 29th, 2018, from https://www.brookings.edu/blog/up-front/2017/11/17/pharmaceutical-industry-profits-and-research-and-development/.
  7. 7.
    Intermountain Health. Leading U.S. Health Systems Announce Plans to Develop a Not-for-profit Generic Drug Company. 2018. Retrieved May 29th, 2018, from https://intermountainhealthcare.org/news/2018/01/leading-us-health-systems-announce-plans-to-develop-a-not-for-profit-generic-drug-company/.

Copyright information

© Society of General Internal Medicine 2018

Authors and Affiliations

  • Karthik Sivashanker
    • 1
  • John Fanikos
    • 2
  • Allen Kachalia
    • 3
    • 4
  1. 1.Harvard Medical School Fellowship in Patient Safety & Quality; Department of PsychiatryBoston University School of Medicine, BostonUSA
  2. 2.Pharmacy DepartmentBrigham & Women’s Hospital, BostonUSA
  3. 3.Department of MedicineBrigham & Women’s Hospital, BostonUSA
  4. 4.Harvard Medical School, BostonUSA

Personalised recommendations